H1 Inc.
| Company type | Private |
|---|---|
| Industry | Healthcare data technology |
| Founded | November 2017 |
| Founder | Ariel Katz, Ian Sax |
| Headquarters | New York City , United States |
Area served | Worldwide |
Key people | Ariel Katz, Ian Sax |
| Products | Da Vinci, Trial Landscape, H1 Explorer |
Number of employees | 400+ (2021) |
| Website | www |
H1 Inc. is an international healthcare data technology firm established in 2017, with its main office located in New York City. The company’s extensive database aids pharmaceutical and healthcare organizations in pinpointing healthcare professionals for collaborative research, thereby facilitating faster development of drugs and treatments. By November 2021, H1 employed more than 400 staff worldwide and catered to approximately 100 clients, including major pharmaceutical corporations such as Novartis and AstraZeneca.
History
The enterprise was launched in November 2017 by Ariel Katz and Ian Sax under the original name H1 Insights. Its primary mission was to link biotechnology and pharmaceutical companies with Key Opinion Leaders (KOLs) to promote advancements in research and drug development. The brand name "H1" symbolizes the "alternative hypothesis" (H) in statistical analysis, standing in opposition to the null hypothesis.
In 2018, H1 introduced its inaugural product, Da Vinci, which provides "Strategy As A Service" aimed at helping life sciences organizations shorten their time-to-market. The company further expanded by joining the Winter 2020 cohort of Y Combinator.
August 2021 marked H1’s acquisition of Carevoyance, a startup based in Portland, enhancing its offerings specifically for medical device clients. By the end of 2021, the workforce had surpassed 400 employees, with a client base exceeding 100, including industry leaders Novartis and AstraZeneca.
In February 2022, H1 extended its capabilities by acquiring Faculty Opinions, a London-based discovery platform that curates top-tier biomedical research from PubMed through expert endorsements. Faculty Opinions indexes over 190,000 recommended articles from more than 4,000 scientific journals.
Products
The foundation of H1’s offerings is its comprehensive database encompassing 160 million peer-reviewed articles, 350,000 clinical trials, 8 billion medical claims, alongside other relevant data points. This information is sourced from public repositories as well as contributions from clients and healthcare providers. The company serves a diverse clientele across pharmaceutical, biotechnology, financial services, data analytics, and healthcare industries. In 2021, H1 rolled out H1 Explorer, a tool enabling healthcare professionals to update and control their profiles within the H1 ecosystem.
Da Vinci was H1’s first market solution launched in 2018 to support pharmaceutical companies in expediting drug development research processes. Subsequently, in September 2021, the company unveiled Trial Landscape to help pharma organizations identify the most suitable clinical trial sites and physician investigators.
Funding
To date, H1 has raised over $200 million through multiple financing rounds:
- Series C: In November 2021, Altimeter Capital led a $100 million round; this was followed by a $33 million extension round in 2022 backed by Goldman Sachs Asset Management, Menlo Ventures, Transformation Capital, and Novartis Pharma AG.
- Series B: December 2020 saw a $58 million round co-led by IVP and Menlo Ventures.
- Series A: In April 2020, Menlo Ventures spearheaded a $12.9 million funding round.
Notable additional investors include Joe Montana, Novartis, Baron Davis, Y Combinator, and Underscore VC.